InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,283.60
(
-0.64%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
84.95
(
-0.06%
)
Bitcoin
64,891.82
(
0.11%
)
Post# of 252279
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119885
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pollyvonwog post# 173437

Thursday, 01/30/2014 1:50:51 PM

Thursday, January 30, 2014 1:50:51 PM

Post# of 252279
(TEVA/MNTA/MYL)—I take issue with the notion that thrice-weekly Copaxone truly represents an “improved dosing regimen.” Inasmuch as 7 is not divisible by 3, a thrice-weekly dosing schedule is suboptimal from a pharmacokinetic standpoint and is only marginally more convenient.

If Teva had conducted a large head-to-head trial of thrice-weekly Copaxone vs daily Copaxone, the thrice-weekly arm would probably have incurred a higher rate of AEs. However, such a trial will never be run by Teva.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up